Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

STMZ Apr. 22 at 2:16 PM

$KALA what happened?

0 · Reply

JustDoItMF Apr. 22 at 2:14 PM

$KALA who knows when they can do RS

1 · Reply

FredoFireUpTheDingy Apr. 22 at 12:32 PM

$KALA reported for manipulation and blocked.

0 · Reply

UrbanCowboy Apr. 22 at 11:56 AM

$KALA

0 · Reply

UrbanCowboy Apr. 22 at 11:55 AM

$KALA this will be a slow bleed with an announcement of a RS or delisting, seen it happen a million times. Get out now before it’s too late!

1 · Reply

JustDoItMF Apr. 21 at 9:30 PM

$KALA everybody wants to win until they're forced to stomach how many losses it really takes. Keep going.

1 · Reply

Beginer_Trading Apr. 21 at 8:32 PM

$KALA how to teach a lesson to these kind of companies? Is there a way?

1 · Reply

JustDoItMF Apr. 21 at 7:50 PM

$KALA dilution is dilution does but lets be honest it will come 2 end and then boom 💥 imo

1 · Reply

STMZ Apr. 21 at 7:46 PM

$KALA

0 · Reply

hockeyfan530 Apr. 21 at 7:27 PM

$KALA lol...looking good

0 · Reply

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Apr 1, 2026, 6:45 AM EDT - 21 days ago

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Mar 30, 2026, 8:45 AM EDT - 23 days ago

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Mar 30, 2026, 8:31 AM EDT - 23 days ago

EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch

Mar 18, 2026, 9:00 AM EDT - 5 weeks ago

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 8:15 AM EDT - 5 weeks ago

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 11, 2026, 11:18 AM EDT - 5 weeks ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Mar 11, 2026, 6:30 AM EDT - 6 weeks ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Mar 4, 2026, 6:30 AM EST - 7 weeks ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Jan 5, 2026, 4:10 PM EST - 3 months ago

KALA BIO Settles Approximately $10.6 million of Debt

Dec 4, 2025, 10:45 AM EST - 4 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Sep 29, 2025, 12:00 PM EDT - 7 months ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Aug 8, 2025, 8:00 AM EDT - 9 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 9 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 9, 2025, 8:00 AM EDT - 10 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 11 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 2 years ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

STMZ Apr. 22 at 2:16 PM

$KALA what happened?

0 · Reply

JustDoItMF Apr. 22 at 2:14 PM

$KALA who knows when they can do RS

1 · Reply

FredoFireUpTheDingy Apr. 22 at 12:32 PM

$KALA reported for manipulation and blocked.

0 · Reply

UrbanCowboy Apr. 22 at 11:56 AM

$KALA

0 · Reply

UrbanCowboy Apr. 22 at 11:55 AM

$KALA this will be a slow bleed with an announcement of a RS or delisting, seen it happen a million times. Get out now before it’s too late!

1 · Reply

JustDoItMF Apr. 21 at 9:30 PM

$KALA everybody wants to win until they're forced to stomach how many losses it really takes. Keep going.

1 · Reply

Beginer_Trading Apr. 21 at 8:32 PM

$KALA how to teach a lesson to these kind of companies? Is there a way?

1 · Reply

JustDoItMF Apr. 21 at 7:50 PM

$KALA dilution is dilution does but lets be honest it will come 2 end and then boom 💥 imo

1 · Reply

STMZ Apr. 21 at 7:46 PM

$KALA

0 · Reply

hockeyfan530 Apr. 21 at 7:27 PM

$KALA lol...looking good

0 · Reply

BlazingStocks Apr. 21 at 6:56 PM

$KALA - With expanded patient access pathways, reduced DEA research restrictions, and national priority review signals from the FDA, Red Light’s psychedelic drug development programs are now positioned to advance with materially stronger regulatory and commercial momentum and to deliver on the full clinical and therapeutic promise of its portfolio within a supportive federal framework. https://www.nasdaq.com/press-release/kala-bio-celebrates-trump-executive-order-game-changer-psychedelic-medicine-2026-04

0 · Reply

SaySomethingNice Apr. 21 at 4:36 PM

$FFAI so beautiful $AIXI $KALA $MBOT

0 · Reply

MikeTechnician Apr. 21 at 4:08 PM

$KALA -News!! ala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine Historic U.S. Executive Order Fast-Tracks Psychedelic Research Access; Landmark Policy Shift Strengthens the Outlook for KALA’s Client Red Light Holland and Positions Researgency.ai as the Dedicated AI Infrastructure Partner for the Global Psychedelic and Biotech Drug Development Industry

0 · Reply

4trax Apr. 21 at 3:58 PM

$KALA so what the hell is going on? Sell the good news

0 · Reply

SaySomethingNice Apr. 21 at 3:42 PM

$FFAI $MBOT $KALA $CUE

0 · Reply

BlazingStocks Apr. 21 at 3:23 PM

$KALA News April 21, 2026 Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine https://www.nasdaq.com/press-release/kala-bio-celebrates-trump-executive-order-game-changer-psychedelic-medicine-2026-04

0 · Reply

SmallCapGrowth Apr. 21 at 3:03 PM

$KALA Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine https://www.nasdaq.com/press-release/kala-bio-celebrates-trump-executive-order-game-changer-psychedelic-medicine-2026-04 The recent U.S. Executive Order fast-tracking psychedelic medicine creates a massive catalyst: ✅ $50M federal funding & priority FDA review for psychedelics. ✅ KALA’s client, Red Light Holland, benefits directly from reduced restrictions. ✅ KALA’s Researgency.ai is positioned as the dedicated AI infrastructure partner for the industry. $KALA is the AI backbone of this new medical frontier. 👀👇 #FrontPageStocks #KALA #Microcap #Biotech #PennyStocks

0 · Reply

JustDoItMF Apr. 21 at 2:37 PM

$KALA im thinking ⬆️ today

0 · Reply

JustDoItMF Apr. 21 at 2:35 PM

$KALA news

0 · Reply

JustDoItMF Apr. 21 at 2:32 PM

$KALA patience doesn't reward the impatient

0 · Reply

UltimateTrader_22 Apr. 21 at 2:30 PM

$KALA News: Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine | NASDAQ https://www.nasdaq.com/press-release/kala-bio-celebrates-trump-executive-order-game-changer-psychedelic-medicine-2026-04

0 · Reply

NorthernMonkey1 Apr. 21 at 2:22 PM

$KALA ape shit? Why are so many of yous so aggy on here haha

0 · Reply

Market Cap	185.90M
Revenue (ttm)	0.00
Net Income (ttm)	-26.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	6,781,800
Avg Vol	8,585,470
Day's Range	N/A - N/A
Shares Out	929.49M
Stochastic %K	19%
Beta	-1.98
Analysts	Strong Buy
Price Target	$1.50